Ann: Annual Financial Results Presentation, page-18

If the FDA don't approve Remestemcel-L for sr-GVHD sooner rather than later (or issue another CRL) people need to understand that there is not enough cash less the Oaktree holding requirement of US $25 million to undertake the CLBP and keep the lights on IMO.


As at 30 June 2024 Mesoblast had access to circa $37 million of useable funds and of course we are almost through the Sept quarter so by my count another approximately $15 million will likely be used in that period. The CLBP trial will be increasing the quarterly spend so you cannot rely on the previous 'reduced' spend that Mesoblast continually tout as it will increase as the CLBP trial progresses - just sayin'


Financially, in my opinion, Mesoblast is screwed if we don't receive an FDA approval or execute a partnership agreement in the Sept quarter / early Oct no matter what the 'acting' CFO or Mesoblast claim and unfortunately that will mean yet another CR if neither of these things happen


GLTAH


Page 9